Flow cytometric analysis of CD122 expression on human PBMC. Human PBMC were stained with PE Mouse Anti-Human CD56 Antibody and either Biotin Mouse IgG1, k Isotype Control (left panel) or SDT Biotin Mouse Anti-Human CD122 Antibody (right panel) at 5 μl/test followed by Sav-APC. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Biotin Mouse Anti-Human CD122 Antibody (S-2880)
Biotin Mouse Anti-Human CD122 Antibody (S-2880)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD122 |
| Synonyms | Interleukin-2 receptor subunit beta; IL-2 receptor subunit beta; IL-2R subunit beta; IL-2RB; High affinity IL-2 receptor subunit beta; Interleukin-15 receptor subunit beta; p70-75 (p75); IL15RB; IL2RB |
| Location | Cell membrane |
| Accession | P14784 |
| Clone Number | S-2880 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD122, also known as the interleukin-2 receptor beta (IL-2Rβ), is a key component of the IL-2 receptor complex and plays a crucial role in regulating immune responses. It is expressed on the surface of various immune cells, including T cells and natural killer (NK) cells. CD122 is involved in mediating the effects of IL-2, which is essential for the proliferation and differentiation of T cells, as well as the maintenance of regulatory T cells (Tregs). Recent studies have shown that targeting CD122 with selective IL-2 complexes can reduce immunosuppression by Tregs and enhance antitumor immunity, making it a promising target for cancer immunotherapy.
Picture
Picture
FC
